3-(5-cyclobutyl-1,3-thiazol-2-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-(oxolan-3-yloxy)benzamide
C24H26N4O3S — CID 148828723
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-(5-cyclobutyl-1,3-thiazol-2-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-(oxolan-3-yloxy)benzamide
3-(5-cyclobutyl-1,3-thiazol-2-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-(oxolan-3-yloxy)benzamide (PubChem CID 148828723) has the molecular formula C24H26N4O3S and a molecular weight of 450.56 g/mol. Its IUPAC name is 3-(5-cyclobutyl-1,3-thiazol-2-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-(oxolan-3-yloxy)benzamide.
Molecular Properties
| Compound Name | 3-(5-cyclobutyl-1,3-thiazol-2-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-(oxolan-3-yloxy)benzamide |
|---|---|
| PubChem CID | 148828723 |
| Molecular Formula | C24H26N4O3S |
| Molecular Weight | 450.56 g/mol |
| Exact Mass | 450.17 |
| IUPAC Name | 3-(5-cyclobutyl-1,3-thiazol-2-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-(oxolan-3-yloxy)benzamide |
| SMILES | Cc1cnc(CNC(=O)c2cc(OC3CCOC3)cc(-c3ncc(C4CCC4)s3)c2)cn1 |
| InChI | InChI=1S/C24H26N4O3S/c1-15-10-26-19(11-25-15)12-27-23(29)17-7-18(9-21(8-17)31-20-5-6-30-14-20)24-28-13-22(32-24)16-3-2-4-16/h7-11,13,16,20H,2-6,12,14H2,1H3,(H,27,29) |
| InChIKey | OTGGBVWXQKXJOW-UHFFFAOYSA-N |
| XLogP | 4.27 |
| TPSA | 86.23 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 450.56 |
| LogP ≤ 5 | 4.27 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 148828723 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.